A comprehensive medical presentation template covering healthcare related topics and most popular human organs. Medical icons are included as a bonus. LINK -> https://www.improvepresentation.com/presentation-templates/medical-presentation-template

1. Medical Presentation
Template Deck
Multiline, sophisticated
subtitle text
Q. RALL
SYDNEY, 14 FEBRUARY 2015

2. Agenda
C L I C K T O A D D S U B T I T L E
1
2
3
4
5
Introduction
Anatomical knowledge behind the discovery
Our method compared to others available
Pros and cons of using the newest drug
Q&A session

3. Multiline chapter
subtitle text
Part One: Introduction

4. Contact Information
B E S U R E T O C O N TA C T U S I N C A S E O F A N Y D O U B T S
I. Q. Rall
i.q.rall@yahoo.com
+1 415 599 2671
228 West 47th Street
New York City
NY 10036

5. And, if we know how to do this, why isn’t everybody
doing it already?
How to prevent the disease?

6. Q&A session
Any questions?

7. Disease Causes
FA C T O R S T H AT L E A D T O I N C R E A S E D S U S C E P T I B I L I T Y
Diabetes
type A
First cause of the disease
Second cause of the disease
Third cause of the disease
Fourth cause of the disease

8. Drug characteristics
L O R E M I P S U M D O L O R S I T A M E T
ONLY NATURAL
COMPONENTS
IMMEDIATE
ACTION
SUITABLE
FOR CHILDREN
LONG LASTING
EFFECTS

9. Disease Symptoms
FA C T O R S T H AT L E A D T O I N C R E A S E D S U S C E P T I B I L I T Y
Diabetes
type A
Diabetes
type A
First cause of the disease
Second cause of the disease
Third cause of the disease
Fourth cause of the disease

10. Summary
L O R E M I P S U M D O L O R S I T A M E T
Summary bullet
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Summary bullet
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Summary bullet
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Summary bullet
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.

11. Milestones
M A J O R E V E N T S I N L I F E T I M E O F T H E P R O J E C T
Birth of
Initial Idea
JANUARY 2011
Milestone
Name
APRIL 2013
Milestone
Name
DECEMBER 2013
Milestone
Name
NOVEMBER 2014
Product Ready
for Market
FEBRUARY 2015
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.

12. The Procedure
S T E P -­‐ B Y-­‐ S T E P I N S T R U C T I O N S
I II III IV
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.
Lorem ipsum
dolor sit amet,
consectetur
adipiscing elit.

13. Disease phases
First phase DescripZon of the phase. Lorem ipsum dolor sit amet.I
Second phase DescripZon of the phase. Lorem ipsum dolor sit amet.II
Third phase DescripZon of the phase. Lorem ipsum dolor sit amet.III
Fourth phase DescripZon of the phase. Lorem ipsum dolor sit amet.IV
Fifth phase DescripZon of the phase. Lorem ipsum dolor sit amet.V

14. Drug specification
L O R E M I P S U M D O L O R E S
15ML
VOLUME
30MG/S
FLOW RATE
0.20MM
PARTICLE SIZE
30MIN
ONSET OF ACTION

15. Subtitle line
The Team Behind the Discovery
John Doe
Head of the
department
Jane Doe
Chief of
research
John Doe
Researcher Lab worker
John Doe

16. “This great idea has
completely changed my
life. I highly recommend
this new approach.”
ANDY
“This great idea has
completely changed my
life. I highly recommend
this new approach.”
REBECCA
“This great idea has
completely changed my
life. I highly recommend
this new approach.”
JOHN

17. Drug Taking Instructions
I M P O R TA N T P O I N T E R S
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.

18. Categories
C L I C K T O A D D S U B T I T L E
Category A
Category B
Category C
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.

19. Subtitle line
Drugs comparison
Drug A Drug B
SALICYLIC ACID IBUPROFENACTIVE INGREDIENT
RISK OF COMPLICATIONS16% 40%
AMOUNT
200MG325MG

20. Method Comparison
CRITERION ONE
CRITERION ONE
CRITERION ONE
CRITERION ONE
CRITERION ONE
Method A Method B Method C

21. Prescription Drug Analysis
PROSCONS
Sed do eiusmod tempor incididunt Lorem ipsum dolor sit amet
Consectetur adipiscing elit
Sed do eiusmod tempor incididunt
Ut labore et dolore magna aliqua
Ut enim
Consectetur adipiscing elit
Lorem ipsum dolor sit amet
Ut labore et dolore magna aliqua
Ut enim

22. Summary of Expenses
L O R E M I P S U M D O L O R E S
TESTS
APPOINTMENTS
MISCELLANEOUS
TEA AND COFFEE
TOTAL
2000 $
7000 $
2500 $
500 $
12 000 $

23. Left Side of Bony Pelvis
A S D E S C R I B E D I N P R O F E S S I O N A L L I T E R AT U R E
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna
aliqua. Ut enim. Lorem ipsum dolor sit
amet, consectetur adipiscing elit.

24. Left Side of Bony Pelvis - main issues
A S D E S C R I B E D I N P R O F E S S I O N A L L I T E R AT U R E
Top corner fraction
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Ut enim.
Bottom end something
Lorem ipsum dolor sit amet, consectetur
adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua.
Ut enim.
1
2
2
1

25. Additional description text
concerning the problem
Challenges we’re facing
Lorem ipsum dolor sit amet,
consectetur adipiscing elit,
sed do eiusmod tempor
incididunt ut labore et
dolore magna aliqua.
1. Lorem ipsum dolor sit amet,
consectetur adipiscing elit,
sed do eiusmod tempor
incididunt ut labore et
dolore magna aliqua.
2. Lorem ipsum dolor sit amet,
consectetur adipiscing elit,
sed do eiusmod tempor
incididunt ut labore et
dolore magna aliqua.
3.

26. Click to add Title
C L I C K T O A D D S U B T I T L E
The art of medicine consists in amusing the patient
while nature cures the disease.
— VOLTAIRE

27. Click to add Title
C L I C K T O A D D S U B T I T L E
Disease name
— SOURCE, YEAR, ADDITIONAL INFO
Dictionary definition of this particular disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit,
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

28. Lorem ipsum dolor sit amet, consec-­‐ tetur adipiscingelit, seddo eiusmod tempor incididuntutlabore.
million people with diabetes
381

29. Multiple Pie Charts
L O R E M I P S U M D O L O R E S
LOREM IPSUM
DOLOR SIT
AMET
84%
16%
LOREM IPSUM
DOLOR SIT
AMET60%
40%
LOREM IPSUM
DOLOR SIT
AMET
84%
16%
LOREM IPSUM
DOLOR SIT
AMET60%
40%
LOREM IPSUM
DOLOR SIT
AMET
84%
16%
LOREM IPSUM
DOLOR SIT
AMET60%
40%
PATIENTS WITH FOOT ULCER PATIENTS WITH HEALTHY FEET

30. Click to add Title
C L I C K T O A D D S U B T I T L E
over
of world’s population
is predicted to be sick
by 2020
45%

31. Drug Reception
C O R R E L AT I O N B E T W E E N D R U G D O S A G E A N D S E V E R A L I N D I C AT O R S
SOURCE: INTERNATIONAL MEDICAL JOURNAL 5/12
DRUG DOSE
CHEMICAL ACTIVITIY
1
2
3
Second indicator
1
2
First indicator
3 Third indicator

32. Drug Reception
C O R R E L AT I O N B E T W E E N D R U G D O S A G E A N D I T S C H E M I C A L A C T I V I T Y
DRUG DOSE
CHEMICAL ACTIVITIY
Observation
Lorem ipsum dolor sit amet, consectetur.
Observation
Lorem ipsum dolor sit amet, consectetur.
Observation
Lorem ipsum dolor sit amet, consectetur.

33. Disease Stadia
L O R E M I P S U M D O L O R E S
Lorem ipsum dolor
sit amet, consectetur
adipiscing elit, sed
do eiusmod tempor
inci-­‐ didunt ut labore
et dolore magna
aliqua. Ut enim ad
minim veniam, quis
nostrud
First Stadium Second Stadium Third Stadium Fourth Stadium
Lorem ipsum dolor
sit amet, consectetur
adipiscing elit, sed
do eiusmod tempor
inci-­‐ didunt ut labore
et dolore magna
aliqua. Ut enim ad
minim veniam, quis
nostrud
Lorem ipsum dolor
sit amet, consectetur
adipiscing elit, sed
do eiusmod tempor
inci-­‐ didunt ut labore
et dolore magna
aliqua. Ut enim ad
minim veniam, quis
nostrud
Lorem ipsum dolor
sit amet, consectetur
adipiscing elit, sed
do eiusmod tempor
inci-­‐ didunt ut labore
et dolore magna
aliqua. Ut enim ad
minim veniam, quis
nostrud
DAY 0 AFTER A WEEK FIRST MONTH AFTER A YEAR

34. Sources of financing
Finances
44%
40%
16%
SOURCE A
SOURCE B
SOURCE C
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT

35. Officially reported cases
L O R E M I P S U M D O L O R E S
0
125
250
375
500
1985 1990 1995 2000 2005 2010 2015
110
199
280
395
297
378
460
SOURCE: INTERNATIONAL MEDICAL JOURNAL 5/12

36. Drug Absorption Age Dependance
0
0,25
0,5
0,75
1
CA 27 YEARS OLD
* Based on official data from US departament’s of health and human services yearly reports

37. Subtitle line
Cycle of disease treatment
SOURCE A SOURCE B
SOURCE C
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
SOURCE C
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
SOURCE A SOURCE B
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT
LOREM IPSUM DOLOR SIT AMET,
CONSECTETUR ADIPISCING ELIT

38. Subtitle text
Disease diagnosis
Healing method
descripZon text
Diabetes
type A
Symptom 1
Symptom 2
Symptom 3
Symptom 4
Symptom 5

39. Influence of regular sport activity
on developing foot ulcer amongst
people with diabetes type A.
Method’s effects *
LOW ACTIVITY
84%
16%
HIGH ACTIVITY
60%
40%
PATIENTS WITH FOOT ULCER
PATIENTS WITH HEALTHY FEET
* Based on official data from US department’s of health and human services yearly reports

40. Method effectiveness in numbers
Method’s effects
2001 2015
33
87
4
No of clinics that
accomodated the method
Patients with treatment
time exceeding one year
Terminal cases count
16
123
28

41. Partners
W E ’ D B E N O W H E R E W I T H O U T T H E M
COMPANY’S NAME COMPANY’S NAME COMPANY’S NAME
COMPANY’S NAME COMPANY’S NAME COMPANY’S NAME

42. Meet Michael Kowalsky
C A S E S T U DY O F O N E O F O U R PAT I E N T S
Michael Kowalsky
28 years old Diabetes Type A
NAME
AGE DIAGNOSIS
NOTES
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos-
trud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

43. Lorem ipsum dolor est.
Our Latest Publication

44. Solution: app
L O R E M I P S U M D O L O R S I T A M E T
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua.

45. Number of cases of disease by region
Progress
1980 2013
164
11656 88
68
84
WEST COAST
MIDWEST
EAST COAST

46. Mentions
W H AT D O T H E S O U R C E S S AY ?
Publication Title
Author, Year
Publication Title
Author, Year
Publication Title
Author, Year

47. References
L O R E M I P S U M D O L O R E S
1. Author Name, Another Name,
2. Author Name, Another Name,
3. Author Name,
4. Author Name,
5. Author Name,
6. Author Name,
7. Author Name, Author Name,
8. Author Name, Author Name,
ArZcle Title. Journal Name vol. no., pages (year).
Book Title (publisher name, publisher locaZon, year), pages.
Book Title (publisher name, publisher locaZon, year), pages.
”Technical Report Title” (report id, publisher, locaZon, year).
”Technical Report Title” (report id, publisher, locaZon, year).
paper presented at the Conference Name, LocaZon, date
paper presented at the Conference Name, LocaZon, date
ArZcle Title. Journal Name vol. no., pages (year).